HF
APGN

HRT Financial’s Apexigen, Inc. Common Stock APGN Stock Holding History

HRT Financial’s Portfolio APGN Stock Details APGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-35,405
Closed -$359K – 3739
2022
Q2 		$359K Buy
35,405
+20,453
+137% +$207K ﹤0.01% 1899
2022
Q1 		$150K Buy
+14,952
New +$150K ﹤0.01% 2561

Other funds holding APGN

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HRT Financial's APGN Position: Q3 2022 in Review

HRT Financial sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2022, closing a stake of 35,405 shares — an estimated $359K sold.

HRT Financial first reported a position in APGN in Q1 2022 and held it in 2 quarters. The position peaked at $359K in Q2 2022. 18 funds tracked by Wall St. Rank hold APGN as of Q3 2022.

  • HRT Financial reported no remaining Apexigen, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • HRT Financial sold 35,405 Apexigen, Inc. Common Stock shares in Q3 2022, an estimated $359K.
  • HRT Financial first reported a position in Apexigen, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • HRT Financial's Apexigen, Inc. Common Stock position peaked at $359K in Q2 2022.
  • 18 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2022.

Based on HRT Financial's 13F filing for Q3 2022, filed 14 Nov 2022.